demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID 19 all comers
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment LIFESAVER
interferon Cai -FAVIPIRAVIR Cai -FAVIPIRAVIR
neutralizing antibody
cilgavimab and tixagevimab (Evusheld) Chen
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose
sarilumab low dose (200mg) sarimulab phase 2 low dose
tocilizumab BACC Bay Tocilizumab Trial TOCOVID
janus kinase (JAK) inhibitor
baricitinib RECOVERY
leflunomide Wang
antiviral and associated therapy
chloroquine and derivatives
chloroquine Chen, ChiCTR2000030054 - Chloroquine
hydroxychloroquine NCT04376814-Group A NOR-Solidarity ... NCT04376814-Group A Gautret et al. IRCT20150808023559N20 ChiCTR2000030054-HCQ ... IRCT20150808023559N20
darunavir cobicistat Jun C
favipiravir Chang Chen et al. NCT04376814-Group A Cai -FAVIPIRAVIR NCT04310228-FAVI ... NCT04376814-Group A Lou ... IRCT20150808023559N20 Calik jRCTs041190120 IRCT20150808023559N20 Cai -FAVIPIRAVIR
hydroxychloroquine plus macrolides Magagnoli ...
nirmatrelvir / ritonavir (Paxlovid) EPIC-SR
remdesivir Norwegian NOR study ... Andreas ...
umifenovir (arbidol) ELACOI ...
miscellaneous
aviptadil COVID-AIV
camostat mesilate Gunst JD
Oral antidiabetic drugs
DPP-4 inhibitor Rhee ... Rhee ... Noh
Renin-angiotensin-system-acting agents Yang Bean Zhang Li Meng Yan et al.
angiotensin receptor blockers (ARBs)
losartan University of Minnesota

12 studies excluded by filtering options 2

5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5521 Del Amo, 2020 200excludedrisk of bias not avaialble
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble